pirfenidone has been researched along with Cytokine Release Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seifirad, S | 1 |
| Aguirre-Plans, J; Artigas, L; Barbera, J; Coma, M; de la Haba-Rodriguez, J; Farrés, J; Fernandez-Fuentes, N; Mas, JM; Matos-Filipe, P; Morales, R; Oliva, B; Olvera, A; Valls, R | 1 |
2 other study(ies) available for pirfenidone and Cytokine Release Syndrome
| Article | Year |
|---|---|
Pirfenidone: A novel hypothetical treatment for COVID-19.
Topics: Alveolar Epithelial Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; Apoptosis; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Disease Models, Animal; Down-Regulation; Drug Repositioning; Humans; Lipid Peroxidation; Oxidative Stress; Pyridones; Receptors, Virus | 2020 |
In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Pharmaceutical; Drug Repositioning; Furin; Humans; Melatonin; Pandemics; Pneumonia, Viral; Pyridones | 2020 |